AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors

ABSTRACT:

Background

Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs.

Methods

Patients with progression disease after failure of platinum-based chemotherapy were enrolled in this study. Anlotinib was orally taken once a day at an initial dose of 12 mg (10 mg when body weight <60 kg). The cycle was repeated every 3 weeks (2 weeks of treatment followed by 1 week rest). There are 3 dose levels (12, 10 and 8 mg), and dose may be reduced to a lower level when grade 3 toxicity occurred. Objective response rate (ORR) and progression-free survival (PFS) were recorded as p

SUBMITTER: Wang C 

PROVIDER: S-EPMC9792827 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature